BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC patients in bemcentinib + KEYTRUDA PhII combination trial
· Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients · Median progression-free-survival (mPFS) of 5.9 months in AXL positive vs 3.3 months in AXL negative patients (~80% improvement) · Predominantly PD-L1 negative or weak-positive patient populationBergen, Norway, 6 November 2018 - BerGenBio ASA (OSE:BGBIO) announces that a Late-breaking Abstract detailing median progression-free-survival (mPFS) during the first stage of its phase II clinical trial with bemcentinib,